Clinical trials: Liver and Intrahepatic Biliary Tract Cancer
Liver Cancer, Pancreas Cancer
A Clinical Trial to Evaluate Safety and Efficacy of Endovascualr Denervation in Treatment of Cancer Pain
A prospective, multicenter, self-control clinical trial aim to enroll 110 patients suffered from upper abdominal (liver, pancreas, stomach, etc.) cancers .
- Conditions
- Liver Cancer, Pancreas Cancer, Stomach Cancer, Bile Duct Cancer
- Trial name
- NCT04014478
- Testing
- Endovascular Denervation
- Volunteers
- 110 people
- Sponsor
- Shanghai Golden Leaf MedTec Co. Ltd
Acquired Bleeding Disorder, Cirrhosis
Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial Hepatectomy
This trial is conducted in Asia. The aim of this trial is to evaluate the haemostatic efficacy of activated recombinant human factor VII in cirrhotic patients scheduled to undergo partial hepatectomy due to liver cancer or benign…
- Trial name
- NCT01562821
- Testing
- activated recombinant human factor VII
- Where
- 7 sites in China, Taiwan and 1 more
- Volunteers
- 235 people
- Sponsor
- Novo Nordisk A/S
Hepatocellular Carcinoma (HCC), Chronic Hepatitis B
Post-Radical Treatment Antiviral Strategies in HBV-Related Liver Cancer: Impact on Tumor Prognosis
The goal of this clinical trial is to learn if peginterferon alfa-2b can reduce the recurrence of HBV-related liver cancer in patients who have undergone radical treatment.
- Trial name
- PRTRAS 001 (NCT07120750)
- Testing
- Intervention for Group 1, Intervention for Group 2
- Volunteers
- 332 people
- Sponsor
- Shenzhen Third People's Hospital
Hepatic Cancer, Hepatic Neoplasm
Endoscopic Ultrasound Guided Liver Biopsy
This is a prospective study to determine the optimal technique for obtaining liver tissue with a smaller caliber (22 gauge) needle and whether a good core biopsy can be obtained without the use of suction and secondly to…
- Conditions
- Hepatic Cancer, Hepatic Neoplasm, Hepatic Carcinoma
- Trial name
- NCT03307811
- Testing
- 22 gauge needle liver biopsy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- AdventHealth
Liver Cancer
A Pilot Study of Perihepatic Phlebotomy During Hepatic Resections
The purpose of this study is to draw blood from vessels near the liver in patients undergoing liver surgery. This will be performed in both patients with cancer in order to learn more about circulating tumor cells, proteins and…
- Trial name
- NCT01749332
- Testing
- Perihepatic Phlebotomy
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hepatocellular Carcinoma
The Detection of Small Early Liver Cancer With Natural History Follow up
The SELINA study will recruit 200 patients with cirrhosis and small HCC and 50 patients with HCC but without cirrhosis (most of whom are expected to have FLD).
- Trial name
- SELINA (NCT05534906)
- Testing
- Blood & Urine Samples, Imaging
- Where
- United Kingdom
- Volunteers
- 250 people
- Sponsor
- University of Oxford
Hepatocellular Carcinoma, Hepatectomy
Stereotactic Body Radiotherapy and Surgery for Early-stage Hepatocellular Carcinoma
The prognosis of small liver cancer (≤5 cm) with stereotactic body radiotherapy (SBRT) is encouraging, the 1-year local control rate has been reported to be 95-100%, 3-year local control rate about 91%, and 3-year overall…
- Conditions
- Hepatocellular Carcinoma, Hepatectomy, Stereotactic Body Radiotherapy
- Trial name
- NCT03609151
- Testing
- laparoscopic hepatectomy (surgery), stereotactic body radiotherapy
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
HBV-related Liver Cirrhosis
Risk Assessment for HBV-Related Liver Cancer
Liver cancer is a severe disease worldwide. The incidence and mortality rates of liver cancer in China is the highest in the world.
- Trial name
- NCT07160946
- Testing
- AI folow-up system
- Where
- China
- Volunteers
- 6,000 people
- Sponsor
- Sun Yat-sen University
Liver Cancer
Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma
RATIONALE: Celecoxib may stop the growth of tumor cells by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00057980
- Testing
- celecoxib, epirubicin hydrochloride
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Northwestern University
Liver Cancer, Adult
The Diagnostic Efficacy and Lesion Detection Advantages of 18F-FDG PET/Contrast-enhanced MRI in Malignant Liver Lesions
Liver disease, a major global health burden, ranges from mild dysfunction to severe conditions like cirrhosis and hepatocellular carcinoma (HCC), the fifth most common cancer.
- Trial name
- NCT07055048
- Volunteers
- 60 people
- Sponsor
- Shanghai East Hospital
Cholangiocarcinoma
The Expression of CD24 "do-not-eat-me" Signal in Cholangiocarcinoma
The investigators found an inverse relationship between CD24 and MiR-122 levels. Then the investigators found that CD24 that goes up with MiR-122 down makes macrophages unable to engulf the tumor cells. All this in mice.
- Trial name
- CD24CCA (NCT06707025)
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Hadassah Medical Organization
Magnetic Resonance Imaging
MR Guidance for Liver and Pancreas
This is a single centre, single arm, prospective feasibility study that aims to see whether magnetic resonance imaging (MRI) as a source of image guidance before each radiation treatment fraction is feasible, and also if it may…
- Trial name
- NCT03582189
- Testing
- MRI
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
Liver Cancer
Effectivity and Safety of Ultrasound-guided Percutaneously Radiofrequency Ablation for Liver Cancer
To evaluate the safety and efficacy of ultrasonography (US) -guided radiofrequency ablation for liver tumors, the investigators used preoperative and postoperative US/CEUS(contrast-enhanced ultrasonography)/CT/MRI to assess…
- Trial name
- NCT03026452
- Testing
- US-guided RFA
- Where
- China
- Volunteers
- 400 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Unresectable or Metastatic Hepatocellular Carcinoma (HCC)
MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.
A Phase 1b/2, open-label, randomized study to evaluate MEDI-573 in combination with standard of care in adult subjects with unresectable or metastatic hepatocellular carcinoma (HCC).
- Trial name
- MEDI-573-1028 (NCT01498952)
- Testing
- MEDI-573 (1 of 3 doses), Sorafenib
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- MedImmune LLC
Fibrolamellar Carcinoma, Fibrolamellar Liver Cancer
Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)
There is no effective standard treatment for fibrolamellar liver cancer that cannot be removed by surgery. The investigators want to find out what effects, good and/or bad, 3 drugs called letrozole, leuprolide and everolimus will…
- Trial name
- NCT01642186
- Testing
- everolimus, letrozole plus leuprolide, combination of everolimus, letrozole and leuprolide
- Where
- 6 sites in United States
- Volunteers
- 28 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer, Hepatocellular, Radiotherapy Side Effect
A Pilot Study For Patients Receiving Radiation Therapy for Liver Cancer
The purpose of this study is to evaluate the role of quantitative MR imaging and blood-based biomarkers to measure liver function in patients receiving radiation therapy for liver cancer or cancer that has spread to the liver.
- Trial name
- HepQuant (NCT06144827)
- Testing
- Multiparametric MRI scans, Multiparametric MRI scans + HepQuantShunt Test
- Sponsor
- Montefiore Medical Center
Breast Cancer, Pancreas Cancer
Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
Phase 1 A: First-in-human phase 1 study to determine safety of NP-G2-044 when given orally on a daily X 28 days followed by a 14 day rest period.
- Conditions
- Breast Cancer, Pancreas Cancer, Prostate Cancer, Lung Cancer
- Trial name
- NCT03199586
- Testing
- NP-G2-044
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Novita Pharmaceuticals, Inc.
Liver Cancer
Irreversible Electroporation(IRE) For Unresectable Portal Venous Tumor Emboli
The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Portal venous tumor emboli.
- Trial name
- IRE (NCT02333773)
- Testing
- Irreversible electroporation (IRE)
- Where
- China
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
This phase II trial is studying how well MD2206 works in treating patients with advanced refractory biliary cancer that cannot be removed by surgery.
- Conditions
- Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma, Recurrent Adult Liver Carcinoma, Recurrent Gallbladder Carcinoma
- Trial name
- NCT01425879
- Testing
- Akt Inhibitor MK2206, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 8 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma, Cholangiocarcinoma
Liver and Biliary Tumor Tissue Registry
Patients having surgery to remove a liver or biliary tissue mass or having a biopsy of a mass or lesion will have a tissue sample collected and stored for future research of liver and biliary diseases.
- Trial name
- NCT02917759
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Mayo Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.